Azenosertib — Drug Intelligence | 5 EU Trials

Filter these 5 trials by condition, phase, country and more.

5 Registered trials

1 Recruiting

3 Completed trials

2 Sponsors

8 Countries

Phase II

Phase I/II

Phase I (Other)

Phase II: 2 Phase I/II: 1 Phase I (Other): 2

Oversight events:

3 temporary halts 6 urgent safety measures 1 corrective measure across 3 trials

Indications tested

5 total

Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting

2022-502983-19-00 Phase II 5 countries K-Group Beta Inc.
LB−100 and azenosertib in metastatic colorectal cancer patients Suspended

2024-511227-33-00 Phase I (Other) 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 Phase II 3 countries K-Group Beta Inc.
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended

2022-502267-37-00 Phase I/II 5 countries K-Group Beta Inc.
Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended

2024-515196-35-00 Phase I (Other) 1 country K-Group Beta Inc.

Showing 1–5 of 5 trials